Theravance Inc news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

THRX 8.58 -0.13 (-1.49%)
price chart
Zacks Short Term Rating on Theravance, Inc. (NASDAQ:THRX)
Research firm Zacks has rated Theravance, Inc. (NASDAQ:THRX) and has ranked it at 3, indicating that for the short term the shares are a hold.
Notable Session Mover: Theravance, Inc. (NASDAQ:THRX)  Vanguard Tribune
Theravance Incorporated (NASDAQ:THRX): Theravance Incorporated remains ...  The Bulletin
Theravance, Inc. (NASDAQ:THRX) Analyst Price Target
Theravance, Inc. (NASDAQ:THRX): The stock price is expected to reach $ 12.25 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $15 while the lower estimate is at $7.
Is Small Cap Theravance Inc (THRX) Turning on the Shorts? GSK, XBI & IBB  SmallCap Network
Where is Theravance, Inc. (NASDAQ:THRX)'s Stock Headed: Analysts  Markets Daily
Why Theravance Inc. Shares Crashed 21% Today
So what: Theravance is the company behind GlaxoSmithKline's (NYSE:GSK) Relvar/Breo Ellipta drug for the treatment of chronic obstructive pulmonary disease, or COPD.
Theravance Just Lost Its Catalyst  Benzinga
Form 8-K THERAVANCE INC For: Sep 08
Company Shares of Theravance, Inc. (NASDAQ:THRX) Rally 11.46%
Shares of Theravance, Inc. (NASDAQ:THRX) appreciated by 11.46% during the past week but lost 46.47% on a 4-week basis.
Company Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Drops by -0.4%  OTC Outlook
Biotech Stocks with Pessimistic Trend: Theravance Inc (NASDAQ:THRX), Raptor ...
On September 27, 2015 GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an exploratory post-hoc analysis of ...
Can Theravance, Inc. (NASDAQ:THRX) hit $15?
The most aggressive covering Wall Street analyst according to Zack's Research has a short-term target price of $15 on Theravance, Inc. (NASDAQ:THRX) shares. When taking into account all of the research brokage firms polled by Zacks, the consensus price ...
Today's Perilous Reversal Stock: Theravance (THRX)
Theravance, Inc., a royalty management company, is focused on developing respiratory products. The stock currently has a dividend yield of 13.9%.
Theravance, Inc. Short Interest Update
Theravance, Inc. (NASDAQ:THRX) ensharesed a drop of 0.5% or -138,909 shares in the short positions. The number dropped from 26,881,318 on August 31,2015 to 26,742,409 on September 15,2015.
Theravance, Inc. (NASDAQ:THRX) Price Target Update  Insider Trading Report
Theravance Inc (THRX) Drops 7.94% on September 28
Theravance Inc (THRX) was one of the Russell 2000's biggest losers for Monday September 28 as the stock slid 7.94% to $7.07, a loss of $-0.61 per share.
Theravance, Inc. Price Target Update
Theravance, Inc. (NASDAQ:THRX): 4 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $12.25 in Theravance, Inc. (NASDAQ:THRX). However, the stock price could fluctuate by $ 3.59 from the estimate as it is ...
Stock in Focus - Theravance, Inc. (NASDAQ:THRX)  Vanguard Tribune
Active Watch List: JPMorgan Chase & Co. (NYSE:JPM), Theravance Inc ...  Stock Transcript